Showing 2641-2650 of 5693 results for "".
- Novavax Initiates Phase 1/2 Trial of COVID-19 Vaccine Candidate NVX‑CoV2373https://modernod.com/news/novavax-initiates-phase-1-2-trial-of-covid-19-caccine-candidate-nvxe28091cov2373/2477822/Novavax on Monday announced that it has enrolled the first participants in a phase 1/2 trial of its coronavirus vaccine candidate NVX‑CoV2373, with preliminary results expected in July. The news follows the Coalition for Epidemic Preparedness Innovations (CEPI) recently awarding up to
- TearClear Appoints Dr. Amir Shojaei Chief Development Officerhttps://modernod.com/news/tearclear-appoints-dr-amir-shojaei-chief-development-officer/2477803/TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer. Over his 23-year career, Dr. Shojaei has focus
- CooperVision Biofinity Toric Multifocal Contact Lenses Now Available Nationwide in the UShttps://modernod.com/news/coopervision-biofinity-toric-multifocal-contact-lenses-now-available-nationwide-in-the-us/2477786/CooperVision has announced that its new Biofinity toric multifocal contact lenses are now available nationwide in the United States. “Amid the COVID-19 pandemic, we understand that eye care practices are operating under various circumstances, and for many, fitting contact lenses still may
- EyePoint Pharmaceuticals Presents Data Showcasing Dexycu at the ASCRS Virtual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-presents-data-showcasing-dexycu-at-the-ascrs-virtual-meeting/2477784/EyePoint Pharmaceuticals announced the presentation of positive retrospective case study data supporting Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery. The data were presented in three electronic posters and one oral pape
- Report: More Than Half of All Age-Related Macular Degeneration Cases Go Undiagnosedhttps://modernod.com/news/report-more-than-half-of-all-age-related-macular-degeneration-cases-go-undiagnosed/2477776/In the nine major pharmaceutical markets, less than half of age-related macular degeneration (AMD) cases were diagnosed in 2019 in adults aged 50 years and older, according to analytics company GlobalData. The company’s latest report, ‘
- LabCorp, Quest Broaden Availability of COVID-19 Tests Nationwidehttps://modernod.com/news/labcorp-quest-broaden-availability-of-covid-19-tests-nationwide/2477766/The U.S. clinical testing giants Quest Diagnostics and LabCorp are broadening the availability of their COVID-19 diagnostic tests, opening up their use nationwide, according to a FierceBiotech
- House Democrats Push New Round of Stimulus Checks in Coronavirus Billhttps://modernod.com/news/house-democrats-push-new-round-of-stimulus-checks-in-coronavirus-bill/2477760/House Democratic leaders are pushing for another round of stimulus payments of up to $1,200 per person in new coronavirus relief legislation that’s headed for a vote Friday, according to an NBC News report.
- Prof. John M. Nolan Receives Heidelberg Engineering Xtreme Research Award 2020https://modernod.com/news/prof-john-m-nolan-receives-heidelberg-engineering-xtreme-research-award-2020/2477755/Prof. John M. Nolan, from the Nutrition Research Centre Ireland, School of Health Science, Waterford Institute of Technology (Ireland), is the recipient of the Heidelberg Engineering Xtreme Research Award 2020 for his research related to macular pigment for vision health and function, as well as
- Artificial Intelligence Algorithm Can Rapidly Detect Severity of Common Blinding Eye Diseasehttps://modernod.com/news/artificial-intelligence-algorithm-can-rapidly-detect-severity-of-common-blinding-eye-disease/2477752/A new artificial intelligence (AI) algorithm developed by researchers at New York Eye and Ear Infirmary of Mount Sinai (NYEE) can rapidly and accurately detect age-related macular degeneration (AMD), according to a company news release. The study, published in the April/May issue of Tr
- VisionCare Announces CE Mark Approval of the Tsert-SI Delivery System for the CentraSight Treatment Programhttps://modernod.com/news/visioncare-announces-ce-mark-approval-of-the-tsert-si-delivery-system-for-the-centrasight-treatment-program/2477744/VisionCare has received CE Mark for the Tsert-SI delivery system for the CentraSight treatment program, which includes the Implantable Miniature Telescope (by Dr. Isaac Lipshitz). The Tsert-SI delivery system includes a pre-loaded telescope implant injector, which only requires a 6.5mm incision,